BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19396154)

  • 1. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.
    Guo CC; Zuo G; Cao D; Troncoso P; Czerniak BA
    Mod Pathol; 2009 Jul; 22(7):866-71. PubMed ID: 19396154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
    Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
    Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
    Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
    Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
    Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.
    Fine SW; Gopalan A; Leversha MA; Al-Ahmadie HA; Tickoo SK; Zhou Q; Satagopan JM; Scardino PT; Gerald WL; Reuter VE
    Mod Pathol; 2010 Oct; 23(10):1325-33. PubMed ID: 20562851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
    Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
    Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
    Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
    Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.
    Toubaji A; Albadine R; Meeker AK; Isaacs WB; Lotan T; Haffner MC; Chaux A; Epstein JI; Han M; Walsh PC; Partin AW; De Marzo AM; Platz EA; Netto GJ
    Mod Pathol; 2011 Nov; 24(11):1511-20. PubMed ID: 21743434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
    Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.